Protagonist Therapeutics, Inc. (PTGX)
| Market Cap | 423.31M |
| Revenue (ttm) | 46.89M |
| Net Income (ttm) | -122.48M |
| Shares Out | 48.66M |
| EPS (ttm) | -2.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 286,401 |
| Open | 8.35 |
| Previous Close | 8.31 |
| Day's Range | 8.15 - 8.84 |
| 52-Week Range | 7.39 - 50.54 |
| Beta | 2.58 |
| Analysts | Buy |
| Price Target | 48.09 (+452.8%) |
| Earnings Date | May 9, 2022 |
About PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinica...
Financial Performance
In 2021, PTGX's revenue was $27.36 million, a decrease of -4.44% compared to the previous year's $28.63 million. Losses were -$125.55 million, 89.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PTGX stock is "Buy." The 12-month stock price forecast is 48.09, which is an increase of 452.76% from the latest price.
News
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspension restored therapeutic benefits including hematocrit control, reduced r...
A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.
ROSEN, A TOP RANKED FIRM, Encourages Protagonist Therapeutics, Inc. Investors With Losses to Inquire About Securities...
New York, New York--(Newsfile Corp. - May 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Prot...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - ...
NEW YORK , May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX). Such investors ar...
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update
Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of focus Presented topline results from the Phase 2 IDEAL study of PN-943 i...
Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,0...
Los Angeles, California--(Newsfile Corp. - April 29, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prot...
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losse...
Los Angeles, California--(Newsfile Corp. - April 28, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prota...
Ongoing Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses o...
Los Angeles, California--(Newsfile Corp. - April 27, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prota...
Why Protagonist Therapeutics Shares Are Crashing Today
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis (UC) patients. 159 patients with moderate-to-severe ...
Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $10...
Los Angeles, California--(Newsfile Corp. - April 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prota...
Protagonist Therapeutics shares slid after sharing Phase 2 data for its experimental ulcerative colitis treatment
Shares of Protagonist Therapeutics Inc. PTGX, -0.58% tumbled 30.8% in premarket trading on Tuesday the day after the company said a Phase 2 clinical trial that gave patients a higher dose of its experim...
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice dai...
Ongoing Investigation Notice: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses ...
Los Angeles, California--(Newsfile Corp. - April 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prota...
TOP RANKED ROSEN LAW FIRM Encourages Protagonist Therapeutics, Inc. Investors with Losses to Inquire About Securities...
NEW YORK , April 24, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Protagonist Ther...
EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to In...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Protagonist Therapeutics, Inc. (...
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, Calif. , April 19, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on April 18, 2022, it issued inducement awards to three recently hired employees in acco...
FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer
Protagonist Therapeutics Inc (NASDAQ: PTGX) received a letter from the FDA indicating the agency's intent to rescind Breakthrough Therapy Designation for the company's rusfertide product candidate in po...
Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies...
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
NEWARK, Calif., March 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced the appointment of Asif Ali as Executive Vice President and Chief Financial Officer (CFO).
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phas...
Phase 2b clinical trial of PN-235, an oral IL-23 receptor antagonist, has launched with a target enrollment of 240 patients NEWARK, Calif., March 16, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasda...
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
NEWARK, Calif., Feb. 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended Decembe...
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.